TransMedics Group, Inc.
TMDX Nasdaq· Electromedical & Electrotherapeutic Apparatus
Last close · Oct 23, 2026
$70.74
KIRA · Stoqly’s AI analyst, in plain words
- TransMedics Group, Inc. had $605M of revenue in fiscal 2025, up 37.1% on the year before. Over five years, revenue changed +88.2% a year on average.
- Its operating margin was 17.9%, up 9.4 pts: of every 100 in sales, about 18 is left after running the business.
- TransMedics Group, Inc. made $190M of net profit in fiscal 2025.
- Free cash flow was $134M in fiscal 2025, 22.1% of revenue.
- TransMedics Group, Inc. has $479M more cash than debt.
Market cap
$2.9B
P/E
18.3x
Revenue
$605M
Net income
$190M
Free cash flow
$134M
Operating margin
17.9%
TransMedics Group, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+37.1%
Yes. Sales grew 37.1% last year.
Does it make a profit?
31.4%
Yes. It keeps 31.4% of every sale as profit.
Does profit turn into cash?
22.1%
Yes. 22.1% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
How is the share priced?
18.3x
One share costs 18.3 times its yearly profit per share.
What TransMedics Group, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- TransMedics Group, Inc.
- CIK
- 0001756262
TransMedics Group, Inc. · TMDX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $30.3M | $93.5M | $242M | $442M | $605M |
| Revenue growth | 18.0% | 208.8% | 158.5% | 82.7% | 37.1% |
| Gross margin | 69.9% | 69.8% | 63.8% | 59.4% | 59.9% |
| Operating margin | −130.3% | −33.6% | −11.9% | 8.5% | 17.9% |
| Net income | −$44.2M | −$36.2M | −$25.0M | $35.5M | $190M |
| Net margin | −146.1% | −38.8% | −10.4% | 8.0% | 31.4% |
| Diluted EPS | −$1.60 | −$1.23 | −$0.77 | $1.01 | $4.87 |
| Cash | |||||
| Cash from operations | −$28.9M | −$45.8M | −$13.0M | $48.8M | $193M |
| Capital expenditure | $3.5M | $11.9M | $152M | $130M | $59.3M |
| Free cash flow | −$32.4M | −$57.7M | −$165M | −$80.9M | $134M |
| FCF margin | −107.0% | −61.8% | −68.2% | −18.3% | 22.1% |
| Share count change | 11.8% | 7.0% | 10.0% | 8.3% | 15.1% |
| Debt and strength | |||||
| Cash and short-term investments | $92.5M | $201M | $395M | $337M | $489M |
| Debt incl. finance leases | $35.2M | $58.7M | — | — | $10.0M |
| Shareholders' equity | $67.9M | $187M | $137M | $229M | $473M |
| Net debt / EBITDA | — | — | — | — | −3.5x |
| Current ratio | 5.1x | 10.7x | 9.3x | 8.3x | 7.1x |
| Interest coverage | −10.2x | −8.4x | −2.7x | 2.6x | 7.9x |
| Returns and quality | |||||
| Return on capital | −293.9% | −55.3% | — | — | — |
| Return on equity | −51.5% | −28.4% | −15.4% | 19.4% | 54.2% |
| Return on tangible equity | −65.2% | −19.3% | −20.4% | 16.5% | 41.4% |
| Piotroski F-score | 3 | 4 | 3 | 5 | 6 |
| Altman Z'' | −7.0 | 1.2 | 1.9 | 2.4 | 4.0 |
Insiders bought, 12 months
$1.1M
2 insiders
Insiders sold, 12 months
$4.9M
7 insiders
Of sales under plans
11%
$0.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
TransMedics Group, Inc. · TMDX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $70.74 a share, the company is worth $2.9B: 18.3 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001756262). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.